PARP inhibitors in epithelial ovarian cancer

KN Taylor, RN Eskander - Recent patents on anti-cancer drug …, 2018 - ingentaconnect.com
Background: Ovarian cancer remains the most common lethal gynecologic malignancy. The
therapeutic gains with the use of traditional cytotoxic chemotherapy in advanced stage …
被引用次数：52 相关文章

PARP Inhibitors in Epithelial Ovarian Cancer

KN Taylor, RN Eskander - Recent patents on anti-cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Ovarian cancer remains the most common lethal gynecologic malignancy. The
therapeutic gains with the use of traditional cytotoxic chemotherapy in advanced stage …

PARP Inhibitors in Epithelial Ovarian Cancer.

KN Taylor, RN Eskander - Recent Patents on Anti-cancer Drug …, 2018 - europepmc.org
Background Ovarian cancer remains the most common lethal gynecologic malignancy. The
therapeutic gains with the use of traditional cytotoxic chemotherapy in advanced stage …